781 – 790 of 2181
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
(
- Contribution to journal › Article
-
Mark
Loss of HIF-1α accelerates murine FLT-3ITD-induced myeloproliferative neoplasia.
(
- Contribution to journal › Article
-
Mark
Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era
(
- Contribution to journal › Article
-
Mark
The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease
(
- Contribution to journal › Article
-
Mark
The applicability of the WHO classification in paediatric AML. A NOPHO-AML study
(
- Contribution to journal › Article
-
Mark
Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.
(
- Contribution to journal › Article
-
Mark
The first specific antiplatelet antidote.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The role of HOXB2 and HOXB3 in acute myeloid leukemia.
(
- Contribution to journal › Article
-
Mark
Association between bleeding tendency and health-related quality of life in carriers of moderate and severe haemophilia.
(
- Contribution to journal › Article
-
Mark
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
(
- Contribution to journal › Article